![]() Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington. In addition, the company develops MASP-2-small-molecule inhibitors for the treatment of aHUS, HSCT-TMA, and age-related macular degeneration GPR174 inhibitors and chimeric antigen receptor T-Cell and adoptive T-Cell therapies for various cancers and G protein-coupled receptors for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. Omeros Corporation (OMER) Stock Price Today, Quote & News Seeking Alpha Premium My Portfolio My Analysts Top Stocks Latest News Markets Stock Ideas Dividends ETFs Education Alpha Picks Is. ![]() It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders OMS906 that is in phase Ib clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders and OMS405 that is in phase II clinical trials for opioid and nicotine addiction. As of 2023 February 08, Wednesday current price of OMER stock is 4. The huge gain came after the company announced that Rayner. About the Omeros Corporation stock forecast. The company’s clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA) that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and Phase II clinical trial to treat COVID-19. The 3 analysts offering 12-month price forecasts for Omeros Corp have a median target of 4.00, with a high estimate of 13.00 and a low. Shares of Omeros Corporation (NASDAQ: OMER) skyrocketed 40.5 higher as of 11:12 a.m. To read this article on click here.Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. (BIO) Stock Analysis Report >Ĭlick for Free Omeros Corporation (OMER) Stock Analysis Report > Click to get this free reportĬlick for Free Bio-Rad Laboratories, Inc. The largest ETF holder of OMER is the Vanguard Total Stock Market ETF (VTI), with approximately 404.38K. ![]() Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Download this IPO Watch List today for free > Four others are a little less obvious but already show jaw-dropping growth. One has driven from 0 to a $68 billion valuation in 8 years. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time. Is OMER going up? Or down? Predict to see what others think: Up or Downīefore looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. According to the current price, Omeros is 48.65 away from the 52-week high. On November 4, billionaire investor and founder of Baron Capital, Ron Baron, made an appearance on CNBC where he discussed his stock-picking style and his overall take on the stock market. You can see the complete list of today’s Zacks #1 Rank stocks here. Its current price per share is approximately 4.03. BIO, sporting a Zacks Rank #1 (Strong Buy). Omeros Corporations stock symbol is OMER and currently trades under NASDAQ. After skyrocketing by above 68.7 on Friday with no clear catalyst to speak of, Omeros ( OMER 6. Omeros Corporation Price | Omeros Corporation QuoteĪ better-ranked stock in the same industry is Bio-Rad Laboratories, Inc.
0 Comments
Leave a Reply. |